428 related articles for article (PubMed ID: 32504692)
1. Small molecule drugs for the treatment of pruritus in patients with atopic dermatitis.
Soeberdt M; Kilic A; Abels C
Eur J Pharmacol; 2020 Aug; 881():173242. PubMed ID: 32504692
[TBL] [Abstract][Full Text] [Related]
2. Emerging Therapeutic Options for Chronic Pruritus.
Reszke R; Krajewski P; Szepietowski JC
Am J Clin Dermatol; 2020 Oct; 21(5):601-618. PubMed ID: 32607945
[TBL] [Abstract][Full Text] [Related]
3. Systemic kappa opioid receptor agonists in the treatment of chronic pruritus: a literature review.
Phan NQ; Lotts T; Antal A; Bernhard JD; Ständer S
Acta Derm Venereol; 2012 Sep; 92(5):555-60. PubMed ID: 22504709
[TBL] [Abstract][Full Text] [Related]
4. Drugs on the Horizon for Chronic Pruritus.
McEwen MW; Fite EM; Yosipovitch G; Patel T
Dermatol Clin; 2018 Jul; 36(3):335-344. PubMed ID: 29929605
[TBL] [Abstract][Full Text] [Related]
5. Topical E6005, a novel phosphodiesterase 4 inhibitor, attenuates spontaneous itch-related responses in mice with chronic atopy-like dermatitis.
Andoh T; Yoshida T; Kuraishi Y
Exp Dermatol; 2014 May; 23(5):359-61. PubMed ID: 24645735
[TBL] [Abstract][Full Text] [Related]
6. Itch Management: Treatments under Development.
Pereira MP; Ständer S
Curr Probl Dermatol; 2016; 50():71-6. PubMed ID: 27578074
[TBL] [Abstract][Full Text] [Related]
7. A randomized, double-blind, vehicle-controlled crossover study to determine the anti-pruritic efficacy, safety and local dermal tolerability of a topical formulation (srd174 cream) of the long-acting opiod antagonist nalmefene in subjects with atopic dermatitis.
Herzog JL; Solomon JA; Draelos Z; Fleischer A; Stough D; Wolf DI; Abramovits W; Werschler W; Green E; Duffy M; Rothaul A; Tansley R
J Drugs Dermatol; 2011 Aug; 10(8):853-60. PubMed ID: 21818506
[TBL] [Abstract][Full Text] [Related]
8. Janus kinase inhibitor delgocitinib suppresses pruritus and nerve elongation in an atopic dermatitis murine model.
Yamamoto Y; Otsuka A; Nakashima C; Ishida Y; Honda T; Egawa G; Amano W; Usui K; Hamada Y; Wada M; Tanimoto A; Konishi N; Hayashi M; Matsushita M; Kabashima K
J Dermatol Sci; 2020 Feb; 97(2):161-164. PubMed ID: 31924380
[No Abstract] [Full Text] [Related]
9. Substance P Antagonist Aprepitant Shows no Additive Effect Compared with Standardized Topical Treatment Alone in Patients with Atopic Dermatitis.
Lönndahl L; Holst M; Bradley M; Killasli H; Heilborn J; Hall MA; Theodorsson E; Holmberg J; Nordlind K
Acta Derm Venereol; 2018 Mar; 98(3):324-328. PubMed ID: 29182791
[TBL] [Abstract][Full Text] [Related]
10. Current pharmaceutical developments in atopic dermatitis.
Misery L; Huet F; Gouin O; Ständer S; Deleuran M
Curr Opin Pharmacol; 2019 Jun; 46():7-13. PubMed ID: 30611103
[TBL] [Abstract][Full Text] [Related]
11. Itch Management: Topical Agents.
Metz M; Staubach P
Curr Probl Dermatol; 2016; 50():40-5. PubMed ID: 27578070
[TBL] [Abstract][Full Text] [Related]
12. Insights into future therapeutics for atopic dermatitis.
Edwards T; Patel NU; Blake A; Prabakaran S; Reimer D; Feldman SR; Strowd LC
Expert Opin Pharmacother; 2018 Feb; 19(3):265-278. PubMed ID: 29376435
[TBL] [Abstract][Full Text] [Related]
13. Involvement of peripheral mu opioid receptors in scratching behavior in mice.
Yamamoto A; Sugimoto Y
Eur J Pharmacol; 2010 Dec; 649(1-3):336-41. PubMed ID: 20863827
[TBL] [Abstract][Full Text] [Related]
14. Antipruritic effect of the topical phosphodiesterase 4 inhibitor E6005 ameliorates skin lesions in a mouse atopic dermatitis model.
Ishii N; Shirato M; Wakita H; Miyazaki K; Takase Y; Asano O; Kusano K; Yamamoto E; Inoue C; Hishinuma I
J Pharmacol Exp Ther; 2013 Jul; 346(1):105-12. PubMed ID: 23674603
[TBL] [Abstract][Full Text] [Related]
15. Treatment of pruritus with topically applied opiate receptor antagonist.
Bigliardi PL; Stammer H; Jost G; Rufli T; Büchner S; Bigliardi-Qi M
J Am Acad Dermatol; 2007 Jun; 56(6):979-88. PubMed ID: 17320241
[TBL] [Abstract][Full Text] [Related]
16. Non-analgesic effects of opioids: peripheral opioid receptors as promising targets for future anti-pruritic therapies.
Reich A; Szepietowski JC
Curr Pharm Des; 2012; 18(37):6021-4. PubMed ID: 22747545
[TBL] [Abstract][Full Text] [Related]
17. Antipruritic mechanisms of topical E6005, a phosphodiesterase 4 inhibitor: inhibition of responses to proteinase-activated receptor 2 stimulation mediated by increase in intracellular cyclic AMP.
Andoh T; Kuraishi Y
J Dermatol Sci; 2014 Dec; 76(3):206-13. PubMed ID: 25458869
[TBL] [Abstract][Full Text] [Related]
18. Role of kappa-opioid and mu-opioid receptors in pruritus: Peripheral and central itch circuits.
Kim BS; Inan S; Ständer S; Sciascia T; Szepietowski JC; Yosipovitch G
Exp Dermatol; 2022 Dec; 31(12):1900-1907. PubMed ID: 36054458
[TBL] [Abstract][Full Text] [Related]
19. Topical E6005/RVT-501, a novel phosphodiesterase 4 inhibitor, for the treatment of atopic dermatitis.
Furue M; Kadono T; Tsuji G; Nakahara T
Expert Opin Investig Drugs; 2017 Dec; 26(12):1403-1408. PubMed ID: 29068253
[TBL] [Abstract][Full Text] [Related]
20. Oral difelikefalin reduces moderate to severe pruritus and expression of pruritic and inflammatory biomarkers in subjects with atopic dermatitis.
Guttman-Yassky E; Facheris P; Da Rosa JC; Rothenberg-Lausell C; Del Duca E; David E; Estrada Y; Liu Y; Bose S; Chowdhury M; Munera C; Goncalves J; Nograles K; Kim BS; Lebwohl M
J Allergy Clin Immunol; 2023 Oct; 152(4):916-926. PubMed ID: 37453614
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
